What Sextant Sees

GSS: 65 | Resonance: 35 | Tension: condensing
Active Patterns: FOMO Ignition, Wrong Consensus Meets Deadline, The Compression Signal
Theoretical: None
Dimensions: M:9.0 C:7.5 D:3 S:5 CP:1 Mg-Q:2 Mg-T:7
Velocity: gaining: C_options_anomaly +7, C_options_put_ratio +6 (24 scans)

THE CHOKEPOINT

ADMA operates FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida plus source plasma collection centers — a vertically integrated supply chain that takes years to replicate. The company secured plasma supply through late 2030s via strategic sourcing deals while competitors face supply constraints. Yield-enhanced production processes at commercial scale drive meaningful gross margin expansion starting 2026.

WHY IT FLAGGED TODAY

ADMA dropped 17% after Culper Research shorted the stock and alleged channel stuffing. Company data shows distributor inventory dropped from 84 to 48 days on hand for ASCENIV between January and March 2026, demonstrating product pull-through. RSI reading of 23.9 signals oversold conditions while consensus EPS estimates increased 81.9% in last 30 days — classic wrong consensus setup.

WATCH FOR

Pre-IND submission for SG-001 candidate targeting pneumonia expected 2026. If successful, SG-001 represents $300-$500 million peak revenue opportunity that could shift the entire valuation framework.

THE ASYMMETRY

Upside: 2026 revenue guidance raised to $635 million with adjusted EBITDA target of $360 million while trading at compressed multiples post-attack. Downside: If Culper's channel stuffing claims prove correct, revenues could decline 3% versus reported 20% growth.

Full entry window, exit conditions, and score trajectory available to Pro members at damonskyeresearch.com

The author may hold positions in securities discussed in this publication. All positions, if any, will be consistent with the analytical thesis presented. DamonSkye Research discloses material holdings at the time of publication. This is not investment advice. See full disclaimer.